Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2002
10/17/2002WO2002081420A1 Cyclooctanone derivative and cyclodecanone derivative, and use thereof
10/17/2002WO2002081415A2 Method for inhibiting metap2
10/17/2002WO2002080987A1 Anti-cd19 immunotoxins
10/17/2002WO2002080979A2 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002WO2002080966A2 Method for producing a vaccine containing autologous antibodies
10/17/2002WO2002080955A1 Stimulation of osteogenesis using rank ligand fusion proteins
10/17/2002WO2002080952A2 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
10/17/2002WO2002080947A1 Compositions containing bacterium capable of converting lactic acid into butyric acid and method of preventing/treating hyperlactic acidemia in digestive tract and colon cancer by using the same
10/17/2002WO2002080936A1 Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
10/17/2002WO2002080935A1 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
10/17/2002WO2002080926A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002WO2002080924A1 Novel use of arylethene sulfonamide derivative
10/17/2002WO2002080914A2 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
10/17/2002WO2002080911A2 Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments for the treatment of neurodegenerative diseases
10/17/2002WO2002080900A1 Method for improving the well-being of poultry by in-ovo injection of carnitine
10/17/2002WO2002080896A1 Uses of benzylideneamino guanidines as ligands to the melanocortiin receptors
10/17/2002WO2002080894A1 Novel use of tyrosine kinase inhibitor
10/17/2002WO2002080887A2 Timed pulse release composition
10/17/2002WO2002080877A2 Use of alverine or one of its salts
10/17/2002WO2002080860A2 Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
10/17/2002WO2002080850A2 Bulking agents as satiety agents
10/17/2002WO2002062301A3 Method and composition for rejuvinating cells, tissues, organs, hair and nails
10/17/2002WO2002054851A3 Inhibition of pathological angiogenesis in vivo
10/17/2002WO2002049626A3 The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity
10/17/2002WO2002047493A3 Health promoting compositions
10/17/2002WO2002040700A3 Corticotropin releasing factor receptor 2 deficient mice and uses thereof
10/17/2002WO2002038607A3 A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor
10/17/2002WO2002034726A3 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
10/17/2002WO2002029061A3 G-protein coupled receptors
10/17/2002WO2002017891A3 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency
10/17/2002WO2002015920A3 Treatment of hyperproliferative diseases
10/17/2002WO2001098323A3 G-protein coupled receptors
10/17/2002WO2001091736A3 Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
10/17/2002WO2001052878A9 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
10/17/2002WO2001041760A8 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/17/2002WO2000000211A3 Hydrocolloids obtained from portulaca oleracea and the use thereof
10/17/2002US20020152481 Genetic engineering; qualitative analysis
10/17/2002US20020151687 Protein/polypeptide-k obtained from momordica charantia and a process for the extraction thereof
10/17/2002US20020151596 Novel process to prepare 2-aminoindan derivatives
10/17/2002US20020151588 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side effects
10/17/2002US20020151586 Antidiabetic agents
10/17/2002US20020151574 Extracellular signal regulated kinase (ERK); anticancer agents and protein kinase inhibitors
10/17/2002US20020151573 Anticancer agents
10/17/2002US20020151569 Peroxisome Proliferator Activated Receptors (PPARs) antagonists 4-oxo-5-thiazolidine acetamide derivatives
10/17/2002US20020151551 Use of growth hormone secretagogues in conjunction with physical exercise cross reference to related application
10/17/2002US20020151536 Substituted azetidinone is used as sterol absorption inhibitor and a fibric acid derivative selected from fenofibrate, clofibrate, gemfibrozil, ciprofibrate, bezafibrate, clinofibrate etc
10/17/2002US20020151501 Compounds having growth hormone releasing activity
10/17/2002US20020151500 Administering a therapeutically effective amount of a type-5 selective somatostatin agonist to patient
10/17/2002US20020151498 Medicaments that modify activity of Lipolysis Stimulated Receptor and that can be used to influence partitioning of dietary lipids between liver and peripheral tissues, including adipose tissue
10/17/2002US20020151483 C3b/C4b complement receptor-like molecules and uses thereof
10/17/2002US20020151480 Identifying a compound to treat a cardiovascular disease, e.g., atherosclerosis, characterized by aberrant 10218 nucleic acid activity or expression; detecting the presence of a nucleic acid in the sample that hybridizes to the probe
10/17/2002US20020151049 Self-enhancing, pharmacologically controllable expression systems
10/17/2002US20020150971 Nucleic acids and polypeptides for controlling food intake and/or body weight
10/17/2002US20020150896 Diagnosis and treatment of diabetes; obtain nucleotide sequence sample from tissue, detect polymorphism, presence of polymorphsm indicates diabetes
10/17/2002US20020150653 Food and vitamin preparations containing the natural isomer of reduced folates
10/17/2002US20020150638 Solid form compositions containing an extract of a raw material as the active ingredient and process of preparing the same
10/17/2002US20020150629 Enhancing absorption; mixture of zinc compound and dipeptide
10/17/2002US20020150624 Mixture of drug, aminoacrylate polymer and acid
10/17/2002DE10118550A1 New 3-ethanoylamino-3-phenyl-propionic acid derivatives, are integrin agonists or antagonists useful e.g. for treating angiogenic, cardiovascular, inflammatory, osteolytic or tumor diseases or infections
10/17/2002DE10117184A1 Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen Substituted imidazol [1,2-a] pyridin-3-yl-amide, and amine compounds of
10/17/2002CA2699611A1 Desaturase genes and uses thereof
10/17/2002CA2698579A1 Desaturase genes and uses thereof
10/17/2002CA2444024A1 Thiohydantoins and use thereof for treating diabetes
10/17/2002CA2443694A1 Anti-cd19 immunotoxins
10/17/2002CA2443099A1 Uses of benzylideneamino guanidines as ligands to the melanocortiin receptors
10/17/2002CA2443085A1 Somatostatin agonists
10/17/2002CA2443057A1 Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
10/17/2002CA2443042A1 Novel use of arylethene sulfonamide derivatives
10/17/2002CA2442996A1 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
10/17/2002CA2442986A1 Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments
10/17/2002CA2442776A1 Antagonists of mcp-1 function and methods of use thereof
10/17/2002CA2442739A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/17/2002CA2442683A1 Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
10/17/2002CA2441538A1 Stimulation of osteogenesis using rank ligand fusion proteins
10/17/2002CA2441499A1 Method for producing a vaccine
10/17/2002CA2441442A1 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002CA2440724A1 Pyrazolopyrimidines as therapeutic agents
10/16/2002WO2001079186A1 2-guanidino-4-arylchinazolines as nhe-3 inhibitors
10/16/2002EP1249450A1 Benzimidazole derivatives
10/16/2002EP1249233A1 Npyy5 antagonists
10/16/2002EP1248849A1 Obg3 globular head and uses thereof for decreasing body mass
10/16/2002EP1248847A1 Irak-4: compositions and methods of use
10/16/2002EP1248842A1 2871 receptor, a g-protein coupled receptor and methods of use thereof
10/16/2002EP1248836A2 Hybrid cells obtainable from antigen presenting cells
10/16/2002EP1248804A2 Recombinant antibodies to human interleukin-1 beta
10/16/2002EP1248801A1 Human polynucleotides, polypeptides, and antibodies
10/16/2002EP1248792A1 Antisense modulation of peroxisome proliferator-activated receptor gamma expression
10/16/2002EP1248785A1 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
10/16/2002EP1248779A2 Glycosidase ihhibitors and preparation thereof
10/16/2002EP1248774A2 Polyhydroxystilbenes and stilbene oxides as antipsoriatic agents and protein kinase inhibitors
10/16/2002EP1248763A2 Aromatic di-keto derivatives as glucose-6-phosphate translocase inhibitors
10/16/2002EP1248652A2 Stable aqueous deoxyfructosazine solution
10/16/2002EP1248643A2 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
10/16/2002EP1248640A1 Preparation and xenotransplantation of porcine islets
10/16/2002EP1248635A1 Antisense modulation of glycogen synthase kinase 3 alpha expression
10/16/2002EP1248633A1 Antisense modulation of glycogen synthase kinase 3 beta expression
10/16/2002EP1248624A1 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS
10/16/2002EP1248615A1 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
10/16/2002EP1248607A1 Urotensin-ii receptor antagonists
10/16/2002EP1248604A2 Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
1 ... 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 ... 1298